Somewhat Positive Media Coverage Somewhat Unlikely to Impact Novartis (NVS) Share Price
Media stories about Novartis (NYSE:NVS) have trended somewhat positive on Sunday, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a news impact score of 0.18 on Accern’s scale. Accern also gave news coverage about the company an impact score of 48.2736191866418 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Novartis Breaks Below 200-Day Moving Average – Notable for NVS (nasdaq.com)
- Bioventures Ltd Novartis Sells 5,615 Shares of Novartis AG (NVS) Stock (americanbankingnews.com)
- Regeneron’s Pain Is Novartis’ Gain (seekingalpha.com)
- GlaxoSmithKline’s Pharmaceuticals Segment in Q2 2018 (finance.yahoo.com)
- Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line (endpts.com)
Several research analysts have recently weighed in on NVS shares. ValuEngine cut shares of Novartis from a “hold” rating to a “sell” rating in a research report on Wednesday, May 2nd. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Thursday, May 17th. Credit Suisse Group raised shares of Novartis from an “underperform” rating to a “neutral” rating in a research report on Friday, May 25th. HSBC cut shares of Novartis from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. Finally, Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a research report on Thursday, June 7th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $93.50.
Novartis (NYSE:NVS) last posted its earnings results on Wednesday, July 18th. The company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.02. Novartis had a net margin of 27.06% and a return on equity of 16.05%. The company had revenue of $13.16 billion for the quarter, compared to analysts’ expectations of $12.93 billion. During the same quarter in the prior year, the company posted $1.22 earnings per share. Novartis’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts anticipate that Novartis will post 5.06 EPS for the current year.
In other Novartis news, major shareholder Bioventures Ltd Novartis sold 30,600 shares of the company’s stock in a transaction dated Monday, July 23rd. The shares were sold at an average price of $4.25, for a total value of $130,050.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 67,214 shares of company stock worth $251,629 in the last ninety days. 0.01% of the stock is currently owned by corporate insiders.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
See Also: Penny Stocks, Risk and Reward Factors
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.